logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Cassava Sciences Promising and Encouraging Results of Its Alzheimer's Disease Product Sumifilam

Cassava Sciences Study Results of Sumifilam for Alzheimer's Disease Prohost is happy to inform our subscribers that our positive opinion about Cassava Sciences' product created and developed for Alzheimer’s disease happens to be right. Cassava Sciences ( SAVA ) announced today...

Read More

September 14, 2020

0

Array BioPharma: Great News and a Learning Experience

Great News for Array BioPharma  Array BioPharma ( ARRY ) announced positive results from the interim analysis of the Phase 3 BEACON CRC trial. The trial evaluates the combination of: Braftovi ®  (encorafenib) , a BRAF inhibitor, Mektovi ®  (binimetinib)...

Read More

May 21, 2019

0

Seattle Genetics: Two New Oncology Collaborations with Merck

Seattle Genetics Two New Strategic Oncology Collaborations with Merck Seattle Genetics ( SGEN ) and Merck ( MRK ) , known as MSD outside the United States and Canada, announced today two new strategic oncology collaborations. The companies will globally...

Read More

September 14, 2020

0

The FDA Cleared Moderna's Coronavirus Vaccine for a Phase 2 Trial. The Stock Surged in Pre-market Hours

Moderna Coronavirus Vaccine Cleared for Phase 2 Moderna ( MRNA ) provided business updates for the first quarter of 2020 and highlighted pipeline progress. The current most important of the news is that the FDA has cleared Moderna’s coronavirus vaccine to...

Read More

May 7, 2020

0

Amgen Is Proving It Is Still the Biotech King. Nektar Forms a Subsidiary Firm to Market Its Pain Product NKTR-181, When Approved

Amgen, the Biotech King A mgen ( AMGN ) , the biotech king, wanted to buy all of the Denmark biotech firm Nuevolution's drug discovery platform. This platform attracted Amgen in 2016 as well as many other large pharma firms...

Read More

May 24, 2019

0

The EMA Granted PRIME Designation to CRISPR Therapeutics’ and Vertex Pharmaceuticals' Product CTX001™ for Severe SCD

Crispr Therapeutics and Vertex Pharmaceuticals CTX001 Granted PRIME Designation by the EMA CRISPR Therapeutics ( CRSP ) and Vertex Pharmaceuticals ( VRTX ) announced that the European Medicines Agency ( EMA ) granted Priority Medicines ( PRIME ) designation to...

Read More

September 22, 2020

0

Recent News from Incyte, Merck and Nektar

Incyte's FDA Approval Based on encouraging data from the REACH1 trial the FDA approved a label expansion of the Incyte ( INCY )   product Jakafi (ruxolitinib)  for graft-versus-host disease (GVHD)  in people 12 years and older. The FDA previously...

Read More

May 29, 2019

0

From ASCO: Amgen, Nektar, Sanofi, GRAIL and Others. A Biotech to Keep an Eye on

What Everyone Wants to Hear from ASCO The American Society of Clinical Oncology (ASCO) meeting is ongoing. What the oncologists, the analysts, the researchers and investors and other interested observers are anxious to hear this year is mostly about the...

Read More

June 4, 2019

0

Bristol-Myers Squibb and bluebird bio Product Ide-Cel, Bb2121 and the FDA Refusal Letter. What Do We Expect?

Bristol-Myers Squibb and bluebird bio  Bristol-Myers Squibb ( BMY ) and bluebird bio ( BLUE ) received a Refusal to File letter from the United States FDA regarding the Biologics License Application ( BLA ), which was submitted in March...

Read More

May 13, 2020

0

Moderna: Pricing of a Public Offering of 17,600,000 Shares at $76.00 Per Share

Moderna Inc: A Public Offering Moderna ( MRNA ) announced the pricing of an underwritten public offering of 17,600,000 shares of common stock at a public offering price of $76.00 per share, before underwriting discounts and commissions. Moderna has also granted the...

Read More

May 19, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 96
  • 97
  • 98
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy